NewsRoom Articles - Page 90 of 154 - PsychedelicNewsWire (PNW)

MondayJul 19, 2021 3:00 pm

Could DMT Sweep Existing Treatments for Depression Aside?

Since research on psychedelics was revived in the 2000s, prompted by the easing of the regulations that govern the substances, a lot of studies have shown that drugs such as LSD and psilocybin possess great therapeutic potential and can be used to treat conditions such as depression, anxiety and addiction. These discoveries have led to the creation of companies that are focused on psychedelic therapy and that are working on finding ways in which these substances can be used in lieu of conventional medicine. Among these companies is Small Pharma, a neuropharmaceutical firm based in the United Kingdom, which is…

MondayJul 19, 2021 11:21 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting and investor relations services Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp…

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

FridayJul 16, 2021 3:00 pm

International Study Finds That Ayahuasca Improves Depression, Anxiety Symptoms

Research has found that psychedelics possess therapeutic benefits that can be used to manage various mental health conditions, including anxiety and depression. Until recently, most studies conducted on these substances had been small scale. The Global Ayahuasca Project, which focused on ayahuasca, is the largest cross-sectional study on the use of ayahuasca to date. Ayahuasca is a pan-Amazonian (South American) psychedelic brew made from the Banisteriopsis caapi vine, which is utilized in ceremonial spiritual medicine as well as socially. The study, which was carried out between 2017–2020, found a connection between improvements in the symptoms of disorders such as depression…

FridayJul 16, 2021 1:45 pm

Dissociation, Dissociative Disorders and Dissociative Psychedelics

The world is deeply interconnected, and we as people may sometimes feel overwhelmed by the happenings in the outside world. If an individual is overwhelmed, their body allows them to disconnect by removing their attention from the present as a form of healthy escape. Called disconnection or dissociation, this is a physiological response to protect oneself, which is activated when the body feels overwhelmed or saturated by too much information or input. There are various kinds of dissociation, including dissociation from one’s sense of self, identity or biographical history; dissociation from one’s awareness or thoughts; and dissociation from one's bodily…

FridayJul 16, 2021 10:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…

ThursdayJul 15, 2021 1:30 pm

Study Finds Mescaline May Trigger Improvements in Psychiatric Symptoms

An exploratory study that was recently published in the “ACS Pharmacology and Translational Science” journal has found that using mescaline has been linked to improvements in anxiety and depression. Mescaline is a psychedelic hallucinogen derived from the peyote cactus. This study provides evidence that some of the useful effects of mescaline are associated with certain facets of the psychedelic experience. Prior research suggests that the use of classic psychedelics may have long-term positive effects. However, the use of mescaline among Native American tribes hasn’t received as much attention as other substances, such as psilocybin. In the study, the researchers note…

WednesdayJul 14, 2021 2:30 pm

Research Suggests Users of Psychedelics Reframe Unpleasant Trips

A study recently asked users of psychedelic substances to share their experiences with the drugs and, in particular, their bad trips. The study, which was reported in the “International Journal of Drug Policy,” found that many users of psychedelic substances used storytelling to redefine bad trips and make them positive experiences. Hallucinogens, or psychedelics, are psychoactive substances that activate altered states of consciousness, influencing an individual’s cognition, perception and mood. Hallucinogens are considered to be low in toxicity and aren’t addictive, but they can sometimes cause challenging trips, which are basically negative reactions that can include frightening hallucinations, panic attacks,…

TuesdayJul 13, 2021 2:45 pm

Third City in California Wants Psychedelics Decriminalized

Yet another city in California is taking steps to pass a resolution aimed at decriminalizing psychedelics. This comes after a council member from Arcata City, California, agreed to spearhead the reform effort. Last week Decriminalize Nature Humboldt revealed that Sarah Schaefer, a councilmember, had accepted the lead in championing a resolution as it makes its way through the council. Schaefer agreed to support the resolution until there is a policy change that makes the enforcement of laws against entheogenic substances, such as ibogaine and psilocybin mushrooms, the lowest priority for law enforcement agencies. In addition, the group announced that during…

MondayJul 12, 2021 3:00 pm

Harvard Launches First-Ever Psychedelics Policy Center

Earlier this week, the Harvard Law School opened a psychedelics policy center, which it believes will be useful to physicians navigating this growing field as more policies of reform are approved. The Project on Psychedelics Law and Regulation, as the center will be known, has been established to promote equity, innovation and safety in psychedelics therapeutics, commerce and research. A press release by the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard acknowledges that local and state psychedelics development involves assessments of the effects of policy as well as the possible impact of private companies that seek…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000